Markus Renschler - Feb 3, 2023 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role: President and CEO, Director
Signature: /s/ Adam M. Veness, as attorney-in-fact for Markus Renschler, M.D.
Stock symbol: CYT
Transactions as of: Feb 3, 2023
Transactions value $: $7,450
Form type: 4
Date filed: 2/7/2023, 03:08 PM
Previous filing: Dec 23, 2022
Next filing: Nov 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Award	$7.45K	+5K	+0.51%	$1.49	984K	Jan 13, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Stock Option (Right to Buy)	Award	$0	+303K		$0.00	303K	Feb 3, 2023	Common Stock	303K	$1.69	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period.
F2	The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

Content

The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period.

The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.